Source:http://linkedlifedata.com/resource/pubmed/id/11082326
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2000-12-12
|
| pubmed:abstractText |
The purpose of this phase I study was to determine the potential efficacy of adenoviral-mediated suicide gene therapy in women with recurrent ovarian cancer. Fourteen patients were treated intraperitoneally with herpes simplex virus-thymidine kinase (HSV-TK)-encoding adenovirus (AdHSV-TK) in dosages ranging between 1x10(9) and 1x10(11) pfu. Beginning 2 days later, ganciclovir (GCV) was administered intravenously at a dose of 5 mg/kg bid for 14 days. Transient vector-associated fever was experienced by 4 of 14 (29%) treated patients. Other possible vector-associated constitutional symptoms, abdominal pain, and gastrointestinal symptoms were experienced by 6 of 14 (43%) treated patients. No other dose-limiting vector-specific side effects were noted. Of the 13 patients evaluable for response, 5 (38%) had stable disease and 8 (62%) had evidence of progressive disease. Molecular analysis of evaluable ascites samples demonstrated the presence of transgene DNA and RNA in most patients 2 days following Ad HSV-TK administration. Ten of 11 evaluable patients had an increase in anti-adenovirus antibody titer. These results suggest that treatment with AdHSV-TK in combination with GCV is feasible in the context of human ovarian cancer and tolerated at the dosages studied.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1525-0016
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
2
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
524-30
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11082326-Adenoviridae,
pubmed-meshheading:11082326-Adult,
pubmed-meshheading:11082326-Aged,
pubmed-meshheading:11082326-Antibodies, Viral,
pubmed-meshheading:11082326-DNA, Viral,
pubmed-meshheading:11082326-Drug Administration Schedule,
pubmed-meshheading:11082326-Female,
pubmed-meshheading:11082326-Ganciclovir,
pubmed-meshheading:11082326-Gene Expression,
pubmed-meshheading:11082326-Gene Therapy,
pubmed-meshheading:11082326-Genetic Vectors,
pubmed-meshheading:11082326-Humans,
pubmed-meshheading:11082326-Injections, Intraperitoneal,
pubmed-meshheading:11082326-Middle Aged,
pubmed-meshheading:11082326-Ovarian Neoplasms,
pubmed-meshheading:11082326-Simplexvirus,
pubmed-meshheading:11082326-Thymidine Kinase,
pubmed-meshheading:11082326-Transgenes
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Adenoviral-mediated suicide gene therapy for ovarian cancer.
|
| pubmed:affiliation |
Department of Obstetrics and Gynecology, National Gene Vector Laboratory, Birmingham, Alabama 35233, USA. rdalvarez@aol.com
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|